Filing Flows › Insmed (INSM) › Q2 2026 › vs Q1 2026
Insmed (INSM) Q2 2026 vs Q1 2026 (quarter over quarter)
Insmed's revenue rose $120M (+39%) from $306M in Q1 2026 to $425M in Q2 2026. The biggest changes: BRINSUPRI +$101M (+49%); ARIKAYCE +$18.2M (+19%).
Insmed, Q2 2026: revenue $425M (+296% year over year), operating margin -0.4%, net loss $13.2M, operating cash flow −$88.8M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| BRINSUPRI | $309M | $208M | $101M | +49% |
| ARIKAYCE | $116M | $98.1M | $18.2M | +19% |
| Revenue | $425M | $306M | $120M | +39% |
| Net loss | $13.2M | $164M | −$150M | -92% |
| Costs & expenses | $439M | $470M | −$30.8M | -7% |
| Operating costs | $427M | $459M | −$32.2M | -7% |
| Interest & other, net | $9.8M | $8.8M | $1.0M | +12% |
| Income tax | $1.9M | $1.5M | $404K | +28% |
| Operating cash sources | $135M | $274M | −$138M | -51% |
| Depreciation & amortization | $5.3M | $5.0M | $245K | +5% |
| Share-based compensation | $41.3M | $45.8M | −$4.5M | -10% |
| Cash used in operations | $88.8M | $223M | −$134M | -60% |
| Net loss absorbed | $13.2M | $164M | −$150M | -92% |
| Working capital & other | $122M | $110M | $12.2M | +11% |
Questions
How much did Insmed's revenue grow quarter over quarter in Q2 2026?
Insmed's revenue rose $120M (+39%) from $306M in Q1 2026 to $425M in Q2 2026.
What drove Insmed's revenue change in Q2 2026?
BRINSUPRI +$101M (+49%); ARIKAYCE +$18.2M (+19%).